• EMA’s CHMP backed marketing authorization for Gilead’s Trodelvy with Merck’s Keytruda in first-line PD-L1-positive metastatic triple-negative breast cancer.
• Opinion covers adults with unresectable locally advanced or metastatic disease, no prior metastatic systemic therapy, PD-L1 CPS ≥10.
• European Commission decision expected later in 2026.
• Recommendation was based on Phase 3 ASCENT-04/KEYNOTE-D19, showing a 35% lower risk of progression or death versus chemo plus Keytruda.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Gilead Sciences Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260723120316) on July 24, 2026, and is solely responsible for the information contained therein.